Infertile men are at higher risk of death, especially those with the most severe form of infertility, although the overall risk is small and lower than that seen in the general population, a study reports.
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.
Patients undergoing assisted reproduction for non-male factor infertility do not derive greater benefit from intracytoplasmic sperm injection (ICSI) over in vitro fertilization (IVF), according to a study presented at ESHRE 2019.
Likelihood of pregnancy following artificial insemination by donor (AID) or in vitro fertilization (IVF) was not negatively affected by using sperm that had been cryopreserved for up to 15 years, according to a study from China.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.